Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · IEX Real-Time Price · USD
0.970
+0.045 (4.90%)
At close: Jul 19, 2024, 4:00 PM
0.880
-0.090 (-9.28%)
Pre-market: Jul 20, 2024, 9:29 AM EDT
Xilio Therapeutics Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for Xilio Therapeutics.
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for XLO.
Recommendation Trends
| Rating | Dec '22 | Jan '23 | Feb '23 | Mar '23 | Apr '23 | May '23 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 1 | 1 | 1 | 1 | 0 |
| Buy | 2 | 2 | 2 | 2 | 2 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 3 | 3 | 3 | 3 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +621.65% | May 30, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Reiterates $7 | Strong Buy | Reiterates | $7 | +621.65% | May 11, 2023 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $20 → $10 | Buy | Maintains | $20 → $10 | +930.93% | Jan 27, 2023 |
| Chardan Capital | Chardan Capital | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +621.65% | Dec 21, 2022 |
| Raymond James | Raymond James | Buy Maintains $31 → $13 | Buy | Maintains | $31 → $13 | +1,240.21% | Nov 10, 2022 |
Financial Forecast
Revenue This Year
15.15M
Revenue Next Year
37.88M
from 15.15M
Increased by 150.00%
EPS This Year
-1.41
from -2.78
EPS Next Year
-0.95
from -1.41
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 31.5M | 78.8M | 13.1M | 1.1M | 98.8M |
| Avg | 15.2M | 37.9M | 6.3M | 336,663 | 33.4M |
| Low | n/a | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 419.8% | -65.3% | -83.4% | 29,248.3% |
| Avg | - | 150.0% | -83.3% | -94.7% | 9,820.0% |
| Low | - | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.66 | 0.01 | -0.50 | -0.44 | -0.37 |
| Avg | -1.41 | -0.95 | -1.00 | -1.21 | -0.48 |
| Low | -2.12 | -1.85 | -1.48 | -1.94 | -0.60 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.